HOME >> BIOLOGY >> NEWS
A New Look At Margerine And Health

Margarines are a healthy choice according to a CSIRO study.

The study, published recently in the American Journal of Clinical Nutrition, indicated that the benefits of polyunsaturated margarines are enhanced when they are also low in trans fatty acids, substances which raise total blood cholesterol.

Clinical trials conducted at CSIRO Human Nutrition in Adelaide, compared the effects of four types of margarine on blood cholesterol. The margarines were polyunsaturated or monounsaturated, with or without trans fatty acids. Thirty eight men and women with mildly elevated cholesterol took part in the feeding trial, lasting 11 weeks.

The results of the study showed that, compared to saturated fat spreads, any of the four margarines reduced the level of LDL (bad) cholesterol in the blood by 11 - 15 per cent. This corresponds to a fall in the risk of heart disease of approximately 20 - 30 per cent. HDL (good) cholesterol was unchanged. In an unexpected finding, the margarine high in polyunsaturates and low in trans fatty acids produced a greater fall in blood LDL-cholesterol than the other margarines.

"The margarine high in polyunsaturates and low in trans fatty acid lowered LDL-cholesterol a further 6 per cent compared to other margarines, a statistically significant difference", said CSIRO researcher Manny Noakes.

"Based on our data, the fall in heart disease risk could be reckoned to be 13 per cent greater with the polyunsaturated margarine without trans fatty acids than a similar spread with trans fatty acids."

Trans fatty acids are a minor class of fats found in small quantities in certain animal products. They used to be present in moderate quantities in margarines. However, there has been an international trend to reduce levels of trans fatty acids in margarines.

Approximately half the margarines on the Australian market do not contain trans fatty acids.

More information:
Manny Noakes, CSIRO, 08-83038827 or
Jenny Rhodes,
'"/>

Contact: Rosie Schmedding
rosie.schmedding@nap.csiro.au
61-2-6276-6520
CSIRO Australia
27-Nov-1998


Page: 1 2

Related biology news :

1. Health of worlds sea lions the focus of Wakefield Symposium
2. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
3. Institute for OneWorld Health nominated for the 2004 World Technology Awards
4. Healthy fats and oils essential to satisfy calorie-conscious consumers
5. Institute for OneWorld Health receives Gates Foundation grant
6. Donaghue Womens Health Investigator Program awards grants to three at Yale
7. OneWorld Health CEO outlines mutually beneficial collaborations between industry, nonprofits at BIO
8. Addressing the Healthcare Needs of Our Aging Population with Technology
9. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health
10. OneWorld Health completes enrollment, treatment in Phase III India trial
11. Institute for OneWorld Health CEO advocates focus first on developing world markets

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Look Margerine And Health

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: